BRAF Fusion

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Childhood Low Grade Glioma6
BRAF V600E OR KIAA1549::BRAF Fusion	Tovorafenib	Predictive	A	Supports Sensitivity Response	5	accepted	EID12016 In this ongoing phase 2 trial (FIREFLY-1), 76 patients, aged 6 months to 25 years, with pediatric low-grade glioma harbouring BRAF alterations (BRAF fusions or BRAF V600E mutations) were treated with … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC	civic
KIAA1549::BRAF Fusion	(prognostic)	Prognostic	B	Supports Better Outcome	4	accepted	EID7193 KIAA1549-BRAF fusion was identified in 87 of 272 patients with PLGGs using Fluorescence In situ hybridization (FISH) analysis. This mutation was strongly associated with a greater progression-free sur… (full text at CIViC) PMID 29948154 · Yang et al., 2018 · Open in CIViC

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Childhood Low Grade Glioma6

BRAF V600E OR KIAA1549::BRAF Fusion

Tovorafenib

Predictive

Supports Sensitivity Response

accepted

EID12016

In this ongoing phase 2 trial (FIREFLY-1), 76 patients, aged 6 months to 25 years, with pediatric low-grade glioma harbouring BRAF alterations (BRAF fusions or BRAF V600E mutations) were treated with … (full text at CIViC)

PMID 37978284 · Kilburn et al., 2024 · Open in CIViC

civic

KIAA1549::BRAF Fusion

(prognostic)

Prognostic

Supports Better Outcome

accepted

EID7193

KIAA1549-BRAF fusion was identified in 87 of 272 patients with PLGGs using Fluorescence In situ hybridization (FISH) analysis. This mutation was strongly associated with a greater progression-free sur… (full text at CIViC)

PMID 29948154 · Yang et al., 2018 · Open in CIViC

Childhood Pilocytic Astrocytoma4
KIAA1549::BRAF Fusion	Selumetinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID7486 In a phase 2 trial, patients with pediatric low-grade glioma after at least one standard therapy were treated with MEK1/2 inhibitor selumetinib. In stratum 1, nine patients with WHO grade I pilocytic… (full text at CIViC) PMID 31151904 · Fangusaro et al., 2019 · Open in CIViC	civic
KIAA1549::BRAF Fusion	Selumetinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID8943 In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with selumetinib resulted in… (full text at CIViC) PMID 28002790 · Selt et al., 2017 · Open in CIViC	civic
KIAA1549::BRAF Fusion	Sorafenib + VemurafenibSubstitutes	Predictive	D	Supports Resistance	2	accepted	EID7402 A pilocytic astrocytoma (PA) cell line named DKFZ-BT66 was generated from a 2-year old patient with the disease. Expression of KIAA1549-BRAF fusion in this cell line was identified. Treatment with sor… (full text at CIViC) PMID 28002790 · Selt et al., 2017 · Open in CIViC	civic
KIAA1549::BRAF Fusion	Trametinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID8944 In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with trametinib resulted in … (full text at CIViC) PMID 28002790 · Selt et al., 2017 · Open in CIViC	civic

Childhood Pilocytic Astrocytoma4

KIAA1549::BRAF Fusion

Selumetinib

Predictive

Supports Sensitivity Response

submitted

EID7486

In a phase 2 trial, patients with pediatric low-grade glioma after at least one standard therapy were treated with MEK1/2 inhibitor selumetinib. In stratum 1, nine patients with WHO grade I pilocytic… (full text at CIViC)

PMID 31151904 · Fangusaro et al., 2019 · Open in CIViC

civic

KIAA1549::BRAF Fusion

Selumetinib

Predictive

Supports Sensitivity Response

accepted

EID8943

In this preclinical experiment, a pediatric pilocytic astrocytoma cell line (DKFZ-BT66) harboring KIAA1549:BRAF fusion was generated from a two year old patient. Treatment with selumetinib resulted in… (full text at CIViC)

PMID 28002790 · Selt et al., 2017 · Open in CIViC

civic

KIAA1549::BRAF Fusion

Sorafenib + VemurafenibSubstitutes

Predictive

Supports Resistance

accepted

EID7402

A pilocytic astrocytoma (PA) cell line named DKFZ-BT66 was generated from a 2-year old patient with the disease. Expression of KIAA1549-BRAF fusion in this cell line was identified. Treatment with sor… (full text at CIViC)

PMID 28002790 · Selt et al., 2017 · Open in CIViC

civic

KIAA1549::BRAF Fusion

Trametinib

Predictive

Supports Sensitivity Response

accepted

EID8944

PMID 28002790 · Selt et al., 2017 · Open in CIViC

civic

Cutaneous Melanoma1
KIAA1549::BRAF Fusion	Trametinib	Predictive	C	Supports Sensitivity Response	1	accepted	EID1571 A 65 yr old male patient with metastatic acral lentiginous melanoma (BRAF, NRAS, KIT negative) was found to harbor a KIAA1549-BRAF (intron 15-intron 8) fusion in a subcutaneous metastasis sample after… (full text at CIViC) PMID 26072686 · Menzies et al., 2015 · Open in CIViC	civic

Cutaneous Melanoma1

KIAA1549::BRAF Fusion

Trametinib

Predictive

Supports Sensitivity Response

accepted

EID1571

A 65 yr old male patient with metastatic acral lentiginous melanoma (BRAF, NRAS, KIT negative) was found to harbor a KIAA1549-BRAF (intron 15-intron 8) fusion in a subcutaneous metastasis sample after… (full text at CIViC)

PMID 26072686 · Menzies et al., 2015 · Open in CIViC

civic

Pilocytic Astrocytoma4
BRAF V600E OR KIAA1549::BRAF Fusion	Selumetinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11316 In this phase II trial on patients with pediatric low-grade glioma were assigned to six unique strata according to histology, tumour location, NF1 status, and BRAF aberration status. This study report… (full text at CIViC) PMID 31151904 · Fangusaro et al., 2019 · Open in CIViC	civic
KIAA1549::BRAF Fusion	(diagnostic)	Diagnostic	B	Supports Positive	5	accepted	EID7148 Genetic alterations in pilocytic astrocytoma (PA) were evaluated. Whole-genome sequencing of normal (blood) and tumor samples (n=96) was performed along with corresponding RNA-Seq (n=73) and mate-pair… (full text at CIViC) PMID 23817572 · Jones et al., 2013 · Open in CIViC	civic
KIAA1549::BRAF Fusion	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID7319 This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytoma but not in 244 higher-grade astrocytomas that were eval… (full text at CIViC) PMID 18974108 · Jones et al., 2008 · Open in CIViC	civic
KIAA1549::BRAF Fusion	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	accepted	EID7337 This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytomas. The fusion gene was shown to delete the N-terminal BR… (full text at CIViC) PMID 18974108 · Jones et al., 2008 · Open in CIViC	civic

Pilocytic Astrocytoma4

BRAF V600E OR KIAA1549::BRAF Fusion

Selumetinib

Predictive

Supports Sensitivity Response

submitted

EID11316

In this phase II trial on patients with pediatric low-grade glioma were assigned to six unique strata according to histology, tumour location, NF1 status, and BRAF aberration status. This study report… (full text at CIViC)

PMID 31151904 · Fangusaro et al., 2019 · Open in CIViC

civic

KIAA1549::BRAF Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID7148

Genetic alterations in pilocytic astrocytoma (PA) were evaluated. Whole-genome sequencing of normal (blood) and tumor samples (n=96) was performed along with corresponding RNA-Seq (n=73) and mate-pair… (full text at CIViC)

PMID 23817572 · Jones et al., 2013 · Open in CIViC

civic

KIAA1549::BRAF Fusion

(diagnostic)

Diagnostic

Supports Positive

accepted

EID7319

This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytoma but not in 244 higher-grade astrocytomas that were eval… (full text at CIViC)

PMID 18974108 · Jones et al., 2008 · Open in CIViC

civic

KIAA1549::BRAF Fusion

(oncogenic)

Oncogenic

Supports Oncogenicity

accepted

EID7337

This study identified a novel rearrangement event between the uncharacterized gene KIAA-1549 and BRAF in 66% (29 of 44) of pilocytic astrocytomas. The fusion gene was shown to delete the N-terminal BR… (full text at CIViC)

PMID 18974108 · Jones et al., 2008 · Open in CIViC

civic

Spindle Cell Sarcoma2
KIAA1549::BRAF Fusion	Bevacizumab + Sorafenib + TemsirolimusCombination	Predictive	C	Supports Sensitivity Response	2	accepted	EID1664 A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinas… (full text at CIViC) PMID 24422672 · Subbiah et al., 2014 · Open in CIViC	civic
KIAA1549::BRAF Fusion	Bevacizumab + Sorafenib + TemsirolimusCombination	Predictive	C	Supports Sensitivity Response	2	accepted	EID7312 A patients with malignant spindle cell tumor treated as as soft tissue sarcoma harboring KIAA1549-BRAF fusion were treated with sorafenib in combination with bevacizumab and temsirolimus. Tumor of th… (full text at CIViC) PMID 26314551 · Ross et al., 2016 · Open in CIViC	civic

Spindle Cell Sarcoma2

KIAA1549::BRAF Fusion

Bevacizumab + Sorafenib + TemsirolimusCombination

Predictive

Supports Sensitivity Response

accepted

EID1664

A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinas… (full text at CIViC)

PMID 24422672 · Subbiah et al., 2014 · Open in CIViC

civic

KIAA1549::BRAF Fusion

Bevacizumab + Sorafenib + TemsirolimusCombination

Predictive

Supports Sensitivity Response

accepted

EID7312

A patients with malignant spindle cell tumor treated as as soft tissue sarcoma harboring KIAA1549-BRAF fusion were treated with sorafenib in combination with bevacizumab and temsirolimus. Tumor of th… (full text at CIViC)

PMID 26314551 · Ross et al., 2016 · Open in CIViC

civic

Unmapped disease1unmapped disease
KIAA1549::BRAF Fusion	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID9694 A novel rearrangement event between KIAA-1549 and BRAF was found in 66% (29 of 44) of pilocytic astrocytomas. The fusion gene was shown to delete the N-terminal BRAF auto-regulatory domain which leads… (full text at CIViC) PMID 18974108 · Jones et al., 2008 · Open in CIViC	civic

Unmapped disease1unmapped disease

KIAA1549::BRAF Fusion

(functional)

Functional

Supports Gain Of Function

submitted

EID9694

A novel rearrangement event between KIAA-1549 and BRAF was found in 66% (29 of 44) of pilocytic astrocytomas. The fusion gene was shown to delete the N-terminal BRAF auto-regulatory domain which leads… (full text at CIViC)

PMID 18974108 · Jones et al., 2008 · Open in CIViC

civic

Evidence by cancer (18 items)

Clinical significance (0)